Humanigen (HGEN)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Humanigen, Inc. (the “Company”) was held on June 17, 2021. Proxies for the Annual Meeting were solicited by the Board of Directors of the Company (the “Board”) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. There were 58,656,689 shares of common stock entitled to vote at the Annual Meeting. A total of 39,983,163 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the Annual Meeting were as follows:

Proposal No. 1

Cameron Durrant, M.D, MBA, Ronald Barliant, JD, Ranier Boehm, M.D., MBA, Cheryl Buxton, M.A., and Dale Chappell, M.D., MBA, were elected by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2022 Annual Meeting of Stockholders by the following vote (in each case until their successors are elected and qualified, or until their earlier death, resignation or removal):

NomineeForWithheldBroker Non-Votes
Cameron Durrant, M.D, MBA26,255,4692,923,12510,804,569
Ronald Barliant, JD26,058,4543,120,14010,804,569
Ranier Boehm, M.D., MBA26,247,2542,931,34010,804,569
Cheryl Buxton, M.A.25,056,6094,121,98510,804,569
Dale Chappell, M.D., MBA28,228,502 950,09210,804,569

Proposal No. 2

The selection by the Audit Committee of the Board of HORNE LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021 was ratified by the following vote:


Proposal No. 3

The compensation paid to the Company’s named executive officers, as disclosed pursuant to